HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 08, August 2019 – Digitalization vs Digitization — Exploring Emerging Trends in Healthcare       » Shanghai neurologists test brain implant to tackle drug addiction       » Gene-editing researchers reduce cancer risk       » Artificial Intelligence in Precision Cancer Diagnostics: Myth or Magic?       » Healing with Technology       » Smart Hospital: An Instrument of Care       » Transforming Healthcare with Data and Artificial Intelligence      
EYE ON CHINA
Chinese patients to see more affordable, high-quality generic drugs
CFDA brings total number of China’s domestic generic drugs to 57

The China Food and Drug Administration recently announced that 16 more generic drugs have been proven equivalent to their original counterparts in both quality and efficacy, bringing the total number of such drugs to 57, People’s Daily Overseas Edition reported on 31 July 2018.

The Generic Quality Consistency Evaluation (GQCE), which has been carried out in China since 2015, is a mandatory bioequivalence test that promotes the quality of China’s domestic generic drugs.

An expert in the field said that the implementation of GQCE is expected to expand the domestic market, create a favourable development environment and promote fair competition for generic drugs, thus helping to lower drug prices.

In April, the Chinese government released a circular focused on improving the supply and utilisation of generics, promoting the quality and efficacy of generic drugs, speeding up the implementation of the GQCE and enhancing quality control of drugs.

According to the circular, the country will provide favourable policies and support to qualified generic drugs in purchasing, pricing, medical insurance coverage and investment. Medical institutions should also give high priority to the use of generic drugs in clinical practice.

According to the GQCE, after the first three manufacturers of a kind of drug pass the assessment stage, no other drug manufacturers will be granted a license to make this drug for the following three years.

An industry insider pointed out that the GQCE is a challenge for domestic generic drug manufacturers, because its implementation will reduce the number of generic drugs on the market by 60 percent. The assessment will, however, motivate manufacturers as the industry becomes normalised and institutionalised.

More than 10 Chinese cities have enacted policies to support the registration of approved generic drugs. For instance, Hubei province in central China has granted a “green passage” to simplify procedures when it comes to introducing approved generic drugs in hospitals.

Source: People’s Daily

Click here for the complete issue.

NEWS CRUNCH  
news Not Science Fiction anymore — the emergence of AI and Robotics in Healthcare
news How blockchain can save the food industry millions from recalls
news China Healthcare and Pharma Digital Innovation Summit
news BIO-PHARM2019 — The Most Influential Forum in China's Biopharm Industry
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy